Predicted protein targets (top 3)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | DGAT1 | O75907 | 4/20 | 0.34 |
| ▸ | NPC1 | O15118 | 1/20 | 0.31 |
| ▸ | PTPN1 | P18031 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL30421153 | 0.86 | DGAT1 (0.39) | DGAT1 | |
| SCHEMBL30421657 | 0.79 | DGAT1 (0.31) | DGAT1 | |
| SCHEMBL20455667 | 0.79 | DGAT1 (0.38) | DGAT1NPC1PTPN1 | |
| SCHEMBL29659291 | 0.79 | DGAT1 (0.38) | DGAT1NPC1PTPN1 | |
| SCHEMBL25236300 | 0.78 | DGAT1 (0.45) | DGAT1NPC1 | |
| SCHEMBL29246501 | 0.76 | DGAT1 (0.34) | DGAT1NPC1PTPN1 | |
| SCHEMBL31514718 | 0.76 | DGAT1 (0.35) | DGAT1 | |
| SCHEMBL14801812 | 0.75 | DGAT1 (0.37) | DGAT1 | |
| SCHEMBL31019222 | 0.75 | DGAT1 (0.36) | DGAT1NPC1 | |
| SCHEMBL29246322 | 0.75 | DGAT1 (0.36) | DGAT1NPC1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20250122191-A1 | COMPOUNDS AS BCL-2 INHIBITORS | FOCHON BIOSCIENCES, LTD. (CN) | 2025-04-17 | — | — | US | disclosed |
| CN-118284608-A | Compounds as BCL-2 inhibitors | 重庆复创医药研究有限公司 | 2024-07-02 | — | — | CN | disclosed |
| CN-118215661-A | Compounds as BCL-2 inhibitors | 重庆复创医药研究有限公司 | 2024-06-18 | — | — | CN | disclosed |
| WO-2024032776-A1 | COMPOUNDS AS BCL-2 INHIBITORS | FOCHON BIOSCIENCES, LTD. (CN) | 2024-02-15 | — | — | WO | disclosed |
| WO-2023088167-A1 | COMPOUNDS AS BCL-2 INHIBITORS | FOCHON PHARMACEUTICALS, LTD. (CN) | 2023-05-25 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20250122191-A1 | COMPOUNDS AS BCL-2 INHIBITORS | BCL2, BCL2L2, BCL2L1 | DGAT1 1390/4885NPC1 1649/4885PTPN1 1622/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.